Chord gets $16m to challenge Alexion with oral NMOSD drugSwiss biotech Chord Therapeutics has come out of stealth mode with a $16 million first-round financing that will Share XChord gets $16m to challenge Alexion with oral NMOSD drughttps://pharmaphorum.com/news/chord-gets-16m-to-challenge-alexion-with-oral-nmosd-drug/
Roche takes on Alexion as FDA approves satralizumab in NMOSDThe FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share XRoche takes on Alexion as FDA approves satralizumab in NMOSDhttps://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
